PMS15 LEFLUNOMIDE IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN POLAND—A BUDGET IMPACT ANALYSIS  by Golicki, D et al.
capital):0.5784(0.0224), Surgical delay (12–24h/0–6h):
1.4374(0.0468), (24-h/0–6h):1.5077(0.0091), Co-morbidities
(yes/no):3.2845(0.0006), (II) with differentiating the co-
morbidities. Age: (70–79/60–69y):1.772(0.0117), (80–89/60–
69y):2.1756(0.0008), (90+/60–69y):4.8668(0), Type of surgery
(os/ap):1.7599(0.0198), Hospital type (university/
capital):0.4656(0.0032), Types of co-morbidities (ICD): C00-
C97:3.0667(0.0006), E10-E16:1.4339(0.0458), F00-
F99:2.0614(0.0003), I30-I52:4.2559(0), I70:1.5504(0.0013),
J00-J22:5.2241(0), L89:1.9277(0.0334). CONCLUSIONS:
Without differentiating co-morbidities, higher age, male gender,
lateral fracture, longer surgical delay, osteosynthesis surgery and
lower progressivity level of primary treatment proved to be of
higher risk for one year mortality. With the differentiation of
co-morbidities the role of surgical delay became weaker, while
certain co-morbidities had higher risk for one year mortality.
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OBJECTIVES: To explore the impact of the October 2004
withdrawal of rofecoxib on the use of surgical treatment for
osteoarthritis, speciﬁcally total hip and knee replacement.
METHODS: Patients were selected from the MarketScan data-
bases who, during January–September 2004, had a diagnosis of
osteoarthritis of the pelvis, thigh, or lower leg (ICD-9-CM
715.*5, 715.*6) on a medical claim and who ﬁlled prescrip-
tions for at least 90 days of therapy with rofecoxib, celecoxib
(an alternative COX-2 inhibitor that continued to be available),
or meloxicam (a patented, non-selective, nonsteroidal, anti-
inﬂammatory drug). For each cohort, the quarterly number of
total hip or knee replacement (THR/TKR) surgeries was
tracked before the withdrawal of rofecoxib (Q1-Q3 2004) and
subsequent to withdrawal (Q4 2004-Q4 2006). RESULTS: The
study cohorts included 31,551 rofecoxib users, 38,388 cele-
coxib users, and 7,007 meloxicam users. During the three quar-
ters prior to the withdrawal of rofecoxib the average quarterly
incidence of THR/TKR in these three cohorts was 2.2%, 1.9%,
and 2.0% respectively. Over the three quarters following the
Vioxx withdrawal, these rates increased to 2.8% for rofecoxib,
2.4% for celecoxib, and 2.6% for meloxicam, then in the next
three quarters decreased to 2.3%, 2.2%, and 2.3% respectively.
Rates of THR/TKR peaked in all groups in Q1 2005. The rate
of growth over Q1 2004 was 45% for rofecoxib, 38% for
celecoxib, and 71% for meloxicam. Quarterly rates of THR/
TKR then declined steadily and at the end of 2006 were similar
to the beginning of 2004. CONCLUSIONS: These results
suggest that the withdrawal of rofecoxib had the result of tem-
porarily increasing the use of THR/TKR to treat osteoarthritis.
This effect was seen not only among rofecoxib users, but also
patients receiving other drugs for whom a major non-surgical
treatment option was removed.
MUSCULAR-SKELETAL DISORDERS—Cost Studies
PMS14
NEW STRATEGIES INTHETREATMENT OF RHEUMATOID
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OBJECTIVES: To evaluate the impact on Italian National
Health Service (NHS) budget of the introduction of Rituximab
(RTX) and Abatacept (ABAT) in the treatment of rheumatoid
arthritis (RA) patients not adequately responding to anti-TNFa
therapies. METHODS: First, RA patients eligible to second-line
biologic treatments and the available strategies for their man-
agement were identiﬁed and quantiﬁed; second, costs associated
to the different alternatives were estimated; ﬁnally, the impact
on the NHS budget was estimated using a cohort simulation
based on a Markov chain with 1-year cycles and a time horizon
of 10 years. Only direct medical costs were considered, includ-
ing drug acquisition, administration, incidental premedication
and monitoring tests and exams RESULTS: Italian RA patients
eligible to second-line biologic therapies were estimated in
about 1,300 per year. Three strategies were identiﬁed as avail-
able: the currently used strategy, based on the switch between
anti-TNFa therapies, and two innovative strategies based on
RTX and on ABAT. The simulated effect of a progressive
replacement (16%, 50%, and 100% at years 1, 5, and 10,
respectively) of the current strategy with the two new strategies
yielded the following results: RTX therapy induces a decrease
of costs of 1.16 million Euro (-7.1% with respect to current
strategy), 4.91 (-7.7%) and 4.94 (-5.3%) at years 1, 5, and 10,
whereas ABAT therapy induces an increase of 0.6 million Euro
(+3.7%), 5.43 (+8.5%) and 20.62 (22.2%). In the direct
comparison between the two new strategies RTX results less
expensive (10.4%, 14.9% and 22.5% at years 1, 5, and 10,
respectively). CONCLUSIONS: The introduction of new thera-
pies in the treatment of Italian RA patients represents a valu-
able option. The use of RTX is expected to induce a reduction
in costs while ABAT probably would produce an increase.
These results are preliminary, more detailed data on the popu-
lation and observed costs are needed.
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Leﬂunomide is recommended as an effective therapeutic option in
patients with methotrexate-resistant rheumatoid arthritis. Its use
in Poland is limited as it is available only in Therapeutic Pro-
gramme. OBJECTIVES: To assess the potential impact on the
Polish health care budget of introducing leﬂunomide reimburse-
ment in rheumatoid arthritis in Poland.METHODS:Analysis was
conducted from the perspective of National Health Fund. Only
direct medical costs including costs of leﬂunomide, DMARDs,
NSAIDs, steroids, outpatients and hospitalizations were consid-
ered. Data from Central Statistical Ofﬁce, Polish Ministry of
Health, National Health Fund, Institute of Rheumatology, IMS
and experts opinion were used. Current total budget spent on
treating rheumatoid patients was estimated. Three different sce-
narios of leﬂunomide use rate were proposed. Time horizon was 5
years. According to AHTAPol guidelines discounting was not
performed. Univariate sensitivity analysis was conducted.
RESULTS: Leﬂunomide reimbursement would impose additional
cost per year on the Polish health care service of PLN6.6 million
(€1.9 million) in the base case scenario. The corresponding range
was estimated at PLN3.0 (€0.9 million) and PLN 28.2 million
(€8.5 million) in the optimistic and pessimistic scenarios, respec-
tively (price level 2008). These costs represent 1.9 % and between
0.9% and 9.6% the total amount currently used on treating
patients with rheumatoid arthritis.CONCLUSIONS: Reimburse-
ment of leﬂunomide for patients with RA should pose a moderate
ﬁnancial burden on the Polish health care system.
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